Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a non-depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation and provides skeletal muscle relaxation during surgery, allowing controlled ventilation and optimal operative conditions.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, with distribution across EU and other regulated markets.

Mivacurium is a non-depolarizing neuromuscular blocking agent used to induce skeletal muscle relaxation during procedures that require controlled ventilation.

- Facilitation of endotracheal intubation: provides rapid, short‑duration paralysis to allow safe placement of the airway tube. - Muscle relaxation during surgery: maintains a relaxed skeletal musculature throughout general anesthesia for optimal surgical conditions. - Diagnostic procedures requiring paralysis: enables brief paralysis for certain imaging or electrophysiological studies.

Mivacurium may cause a range of adverse reactions, from mild to severe, that clinicians monitor during use.

Common Side Effects: - Flushing: transient redness of the skin. - Hypotension: mild to moderate drop in blood pressure. - Bronchospasm: narrowing of the airways causing wheezing. - Injection site pain: discomfort at the site of IV administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged apnea: extended respiratory paralysis beyond expected duration. - Malignant hyperthermia: life‑threatening hypermetabolic crisis. - Cardiac arrest: sudden loss of heart function. - Severe hypotension: marked drop in blood pressure leading to shock. - Respiratory depression: inadequate breathing requiring ventilatory support.

When using Mivacron, careful assessment and monitoring are essential to minimize risks.

- Dose adjustment in hepatic impairment: reduce dose as metabolism may be prolonged. - Avoid in patients with known hypersensitivity to mivacurium or related compounds: discontinue use. - Monitor neuromuscular function continuously during administration: use a peripheral nerve stimulator. - Be prepared to manage bronchospasm: have bronchodilators readily available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that affect neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid): - Concurrent use of potent cholinesterase inhibitors (e.g., neostigmine) may prolong neuromuscular blockade. - Combination with other neuromuscular blocking agents can cause additive paralysis. - Co‑administration with magnesium sulfate may enhance blockade.

Moderate Interactions (Monitor Closely): - Use with volatile anesthetics may increase duration of action. - Concurrent use of beta‑adrenergic blockers may affect cardiovascular response. - Administration alongside antihistamines may mask early signs of an allergic reaction.